Europe
Paris-based Sanofi reported its third-quarter finances, with most of its categories showing strong growth. However, not everything was rosy
Although the literature suggests this condition may affect 200 people globally, Williams and his team think the numbers are higher.
The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.
Cell and gene therapies are at an inflection point, as increasing quantities of clinical data highlight both their potential and their challenges.
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
The clinical study on ANG-3777 demonstrated a modest but not clinically significant difference in the placebo group’s estimated glomerular filtration rate.
BioNTech plans to increase its manufacturing capacity in Africa over time through the supplementation of new manufacturing lines and construction of additional manufacturing sites.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
Janssen reported analyses in which STELARA is showing promising results as a first-line therapy for Crohn’s Disease (CD) and Ulcerative Colitis (UC).
It was yet another busy week for clinical trial news. Here’s a look.
PRESS RELEASES